Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN V versus AUREOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN V versus AUREOMYCIN.
ACHROMYCIN V vs AUREOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-tRNA binding to mRNA-ribosome complex.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
250-500 mg orally every 6 hours
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic